One Year Later

Our Reflections on Foreign Aid, Vaccine Science, Research Opportunities and the Future of Global Health

“The last year has been one of chaos, anger, panic, and frustration. I think the coming year has to be one of strategic rebuilding and building something different—not building back but building forward. That means a different architecture at the country level, community level, regional level, and global level. A year from now, I suspect we’ll see fewer acronyms, but hopefully the ones that remain will be stronger than ever.” —AVAC’s Mitchell Warren, Bhekisisa podcast

This week marks one year since the US Presidential Administration issued a deeply cruel executive order freezing foreign assistance, halting billions of dollars in already-approved funding under the bad-faith claim of a “90-day review”. What followed was not a brief pause, but a drawn-out, chaotic disruption that stopped life-saving work across the globe, shutting down valuable organizations, and harming lives, health, and livelihoods. And that was just the beginning of a year of chaos.

To mark this moment, AVAC’s One Year Later series reflects on the impact of the past 365 days on five key areas of global health and development:

  1. The erosion of US foreign aid
  2. The assault on vaccine science and policy 
  3. The dismantling of the research enterprise 
  4. The cruel irony of funding cuts in the context of the breakthrough technology of long-acting lenacapavir for PrEP 
  5. The profound shifts underway in global health architecture

These pieces show how the field navigated a year defined by disruption and resilience—and how policy decisions reverberate through science, programs, and communities. 

The year has been a profoundly transformative one for AVAC. The Devex in-depth retrospective, Fighting for Billions: The legal battle to keep US foreign aid alive, chronicles the ongoing lawsuits brought by AVAC, the Global Health Council and partners challenging the foreign aid freeze. The piece highlights how legal action became a critical line of defense against the dismantling of lifesaving programs and why the outcome still matters.

“For me, the best message I can say is a year later, we as a community are still standing. And that is a resilience in its own right. We are going to succeed in global health and development. Not because of what happened in the last year, but in spite of it.” —AVAC’s executive director Mitchell Warren on Bhekisisa’s new podcast, One year after Trump: The day HIV funding changed forever—and what came next

As Jeanne Marrazzo, the new CEO of the Infectious Diseases Society of America (IDSA) shared on our webinar earlier this week showcasing the 2025 update of the People’s Research Agenda (PRA), “We cannot yell it from the rooftops loud enough that new infections are going to rise and undermine efforts to end AIDS as a public health threat. But this is not a time to despair. It’s a time to fight. It’s a time to dig in and recognize not just what we’ve accomplished and why we need to protect that, but why we need to continue to move forward.” See the recording here and learn more about the PRA, which tracks the science, highlights where investments align—or fail to align—with community priorities and identifies critical gaps that must be addressed to ensure the prevention pipeline meets the needs of diverse populations.  

The past year has reshaped global health—and AVAC—in ways that will be felt for years to come. The events of the past year also show that advocacy, evidence, and community leadership matter. Some courts provided the necessary check on power; advocates rallied; and scientists and civil society raised their voices and documented what was lost—and what must be protected (see 24 Hours to Save AIDS Research). 

With your support, AVAC’s weekly Global Health Watch newsletter, now in its 52nd week, continues to track what happens, elevate what’s at risk, and help all of us navigate what comes next. Thank you to our community which stops at nothing to safeguard hard-won progress against HIV and in advancing global health equity.

Avac Event

The Future of HIV Prevention: A People’s Research Agenda for Speed, Scale and Equity

First developed in 2024 in partnership with global advocates and communities, the People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. The PRA tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

  • Featured speaker Jeanne Marrazzo, CEO of the Infectious Diseases Society of America and AVAC board member.
  • We covered what the People’s Research Agenda tracks, why it matters, and the advocacy priorities that will shape the future of prevention R&D.

View Recording / Download Slides

AVAC Input for Recompetition of the NIAID HIV/AIDS Clinical Trials Networks

AVAC’s formal input submitted on the re-competition of the NIAID HIV/AIDS Clinical Trials Networks. The recommendations were informed by the People’s Research Agenda (PRA), a comprehensive framework developed through consultations with over 130 community representatives across 23 countries.

Avac Event

South African AIDS Conference (SAAIDS)

The 12th SAAIDS Conference 2025, under the theme: Unite for Change – Empower Communities and Redefine Priorities for HIV/AIDS will be held in Johannesburg 8-11 September.

Resources

If you’re attending, don’t miss a keynote plenary where AVAC’s Mitchell Warren will share perspectives on the future of HIV prevention, and an important satellite on Wednesday, Bridging the Gap and Identifying Opportunities: Innovative Strategies to Accelerate HIV Prevention, Treatment, and Care for Key and Vulnerable Populations in South Africa.  

Global Advocates Welcome the Launch of Merck’s EXPrESSIVE Program

Known as the EXPrESSIVE program, the drug maker Merck has two trials testing a monthly pill for PrEP. Merck is committed to stakeholder engagement, putting global advocates at the forefront of planning for the program. Numerous organizations and advocates commend Merck’s dedication to hearing from the community and shared this statement.

Designing for the Future

Community perspectives for HIV prevention trials

Presented by AVAC’s Regional Program Manager for Research Engagement Grace Kumwenda at IAS 2025, this presentation summarizes community demands that future HIV prevention trials be ethical, acceptable, inclusive, feasible, and efficient.

The Scientific Journey of Lenacapavir — and the Urgency to Defend HIV Prevention Science 

On June 11, AVAC hosted a conversation, The Scientific Journey of Lenacapavir: From basic science to clinical development to impact, to explore how US support from NIH for basic science and South Africa’s clinical research infrastructure made possible the development of lenacapavir for PrEP (LEN), a discovery in HIV prevention that went on to be named Science magazine’s 2024 Breakthrough of the Year.

As the field anticipates initial regulatory approval from the US FDA by June 19 and a WHO recommendation in July, Linda-Gail Bekker of the Desmond Tutu Health Foundation, Wes Sundquist of the University of Utah and Mitchell Warren of AVAC underscored how this moment of promise is threatened by sweeping attacks on science, research and the very systems that made the development of LEN possible.

Avac Event

100 Days In: How HIV Advocates are Meeting the Moment

In its first 100 days, the Trump administration proposed deep cuts to public health and HIV funding, attacked evidence-based healthcare, defunded scientific research, rolled back protections for LGBTQ+ people, and emphasized punitive criminal legal approaches. These moves pose serious threats to the future of HIV-related services, care, prevention, and the broader struggle for health equity and racial justice in our multiracial democracy.

Join CHLP for this moderated panel discussion focused on what the first 100 days of the Trump administration have meant for our communities, particularly people living with HIV, Black and brown people, LGBTQ+ people, and those impacted by criminalization, and how we are collectively shifting strategy to meet the current political moment.

Panelists

  • Michael Elizabeth, Equality Federation
  • Venita Ray, Black South Rising
  • John Meade, PrEP in Black America, AVAC
  • Chauncey McGlathery, American Academy of HIV Medicine
  • Jada Hicks & Sean McCormick, CHLP

Why HIV Prevention Must Not Be Left Behind

In this presentation at the INTEREST 2025 conference, Rhoda Msiska of Copper Rose Zambia emphasizes the urgency of protecting the progress made in scaling up PrEP and the need to act now to expand access to new HIV prevention tools like injectable lenacapavir (LEN) and the Dual Prevention Pill (DPP).

Novel Study Designs for New HIV Prevention Products

A presentation by Deborah Donnell, of the Fred Hutchinson Cancer Research Center University of Washington, discussing trial design when PrEP is available. How can the field justify randomization to an experimental drug when we have something known to work? If we give study participants PrEP, how can we know a new experimental drug is working?